Biofidelity and CellCarta Partner to Bring Aspyre Lung to Global Clinical Trials

• Biofidelity and CellCarta have announced a strategic partnership to utilise Aspyre Lung in global clinical trials.

• The collaboration aims to simplify non-small cell lung cancer (NSCLC) biomarker detection through innovative genomic profiling technology.

Biofidelity, a company specialising in innovative genomic solutions, has partnered with CellCarta, a global contract research organisation (CRO), to integrate the Aspyre Lung platform into clinical trials worldwide. The partnership seeks to enhance the detection of NSCLC biomarkers, expediting clinical trial enrolment and advancing precision medicine.

Under the agreement, CellCarta will validate and implement Aspyre Lung in its European laboratories, followed by expansion to its US-based facilities. Aspyre Lung is designed to analyse DNA and RNA from tissue and liquid biopsy samples using a simplified four-step workflow, compatible with existing qPCR platforms. This technology enables seamless laboratory integration and aligns with CellCarta’s commitment to innovative biomarker services.

Barnaby Balmforth, PhD, Co-Founder and CEO of Biofidelity, expressed enthusiasm for the collaboration, stating, “At Biofidelity we’re actively working toward a future where more people around the world have access to the life-changing power of genomics.” He added that the partnership would facilitate faster and more efficient clinical trial enrolment.

Dusty Tenney, CEO of CellCarta, highlighted the significance of the partnership, saying, “The addition of Aspyre Lung to our capabilities marks an advancement in our mission to propel precision medicine with specialised laboratory services.”